A new approach to disease-modifying drug trials in Parkinson's disease.


Journal Article

Translating new findings in the laboratory into therapies for patients is a slow and expensive process. The development of therapies for neurodegenerative diseases is further complicated by the difficulty in determining whether the drug truly retards the slow degenerative process or provides only symptomatic benefit. In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD) patient study using a drug previously approved for diabetes treatment. In addition to suggesting that the drug may indeed be disease modifying in PD, their innovative approach suggests there may be more rapid and inexpensive avenues for testing novel therapies in PD.

Full Text

Cited Authors

  • Barker, RA; Stacy, M; Brundin, P

Published Date

  • June 2013

Published In

Volume / Issue

  • 123 / 6

Start / End Page

  • 2364 - 2365

PubMed ID

  • 23728166

Pubmed Central ID

  • 23728166

Electronic International Standard Serial Number (EISSN)

  • 1558-8238

International Standard Serial Number (ISSN)

  • 0021-9738

Digital Object Identifier (DOI)

  • 10.1172/JCI69690


  • eng